Hirsch Index: 67 - (i10 index: 183)
ResearchGate
Chronology of Publications
254) Ketone bodies rescue mitochondrial dysfunction via epigenetic remodeling.
Gambardella J, Jankauskas SS, Kansakar U, Varzideh F, Avvisato R, Prevete N, Sidoli S, Mone P, Wang P, Lombardi A, Santulli G.
JACC BTS. 2023;8(9):1123–1137. doi: 10.1016/j.jacbts.2023.03.014.
253) Cardiac Sarcoidosis: Updated Insights on Epidemiology and Diagnostic Criteria.
Santulli G.
American Journal of Cardiology. 2023;204:425. doi: 10.1016/j.amjcard.2023.07.123.
252) Infiltrating macrophages amplify doxorubicin-induced cardiac damage: role of catecholamines.
Gambardella J, Santulli G, Fiordelisi A, Cerasuolo FA, Wang X, Prevete N, Sommella E, Avvisato R, Buonaiuto A, Altobelli GG, Rinaldi L, Chiuso F, Feliciello A, Dal Piaz F, Campiglia P, Ciccarelli M, Morisco C, Sadoshima J, Iaccarino G , Sorriento D.
Cellular and Molecular Life Sciences. 2023;80:323.
251) Molecular Mechanisms Underlying Pluripotency and Self-Renewal of Embryonic Stem Cells.
Varzideh F, Gambardella J, Kansakar U, Jankauskas SS, Santulli G.
Int J Mol Sci. 2023;24(9):8386.
250) miR-181c targets Parkin and SMAD7 in human cardiac fibroblasts: Validation of differential microRNA expression in patients with diabetes and heart failure with preserved ejection fraction.
Jankauskas SS, Mone P, Avvisato R, Varzideh F, De Gennaro S, Salemme L, Macina G, Kansakar U, Cioppa A, Frullone S, Gambardella J, Di Mauro M, Tesorio T, Santulli G.
Mech Ageing Dev. 2023;212:111818.
249) Long-lasting Control of LDL-Cholesterol Induces a Forty Percent Reduction in the Incidence of Cardiovascular Events: New Insights from a 7-year Study.
Trimarco V, Izzo R, Gallo P, Manzi MV, Forzano I, Pacella D, Santulli G (Corresponding Author; co-last Author), Trimarco B.
J Pharmacol Exp Ther (JPET). 2023; in press.
248) SGLT2 Inhibitors: an Evidence-Based Update on Cardiovascular Implications.
Forzano I, Wilson S, Lombardi A, Jankauskas SS, Kansakar U, Mone P, Varzideh F, Santulli G.
Expert Opinion on Investigational Drugs. 2023; in press; doi: 10.1080/13543784.2023.2263354.
247) Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease.
Gambardella J, Fiordelisi A, Cerasuolo FA, Buonaiuto A, Avvisato R, Viti A, Sommella E, Merciai F, Salviati E, Campiglia P, D'Argenio V, Parisi S, Bianco A, Spinelli L, Di Vaia E, Cuocolo A, Pisani A, Riccio E, Di Risi T, Ciccarelli M, Santulli G, Sorriento D, Iaccarino G.
iScience. 2023;26(3):106074.
246) COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells.
Jankauskas SS, Kansakar U, Sardu C, Varzideh F, Avvisato R, Wang X, Matarese A, Marfella R, Ziosi M, Gambardella J, Santulli G.
Antioxidants. 2023;12(2):326.
245) Myosin activator omecamtiv mecarbil exhibits divergent inotropic and lusitropic effects in cardiac slices from patients with heart failure.
Varzideh F, Mone P, Salemme L, Forzano I, Cioppa A, Tesorio T, Santulli G.
JMCC Plus. 2023; in press.
244) Insights in cardiovascular endocrinology: 2023.
Santulli G.
Front Endocrinol. 2023;14:1266221. doi: 10.3389/fendo.2023.1266221.
243) Mitochondrial Calcium Overload Plays a Causal Role in Oxidative Stress in the Failing Heart.
Dridi H, Santulli G, Bahlouli L, Miotto M, Weninger G, Marks AR.
Biomolecules 2023;13(9):1409. doi: 10.3390/biom2590553
242) Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in Diabetic patients with Acute Myocardial Infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT Registry.
Paolisso P, Bergamaschi L, Cesaro A, Gallinoro E, Gragnano F, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Belmonte M, Esposito G, Morici N, Andrea Oreglia J, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Calabrò P, Barbato E, Marfella R, Pizzi C.
Diabetes Res Clin Pract. 2023;202:110766.
241) Translational Aspects of Cardiovascular Biology: From Bench to Bedside.
Santulli G.
Biology. 2023;12(5):658. doi: 10.3390/biology12050658.
240) Effects of moderate caffeine intake in athletes.
Mone P, Guerra G, Verderosa S, Santulli G, Komici K.
European Journal of Internal Medicine. 2023; in press.
239) The therapeutic concordance approach reduces adverse drug reactions in patients with resistant hypertension.
Trimarco V, Manzi MV, Izzo R, Mone P, Lembo M, Pacella D, Esposito G, Falco A, Morisco C, Gallo P, Santulli G (Corresponding Author), Trimarco B.
Front Cardiovasc Med. 2023;10:1137706.
238) Insulin Resistance Drives Cognitive Impairment in Hypertensive Prediabetic Frail Elders: The CENTENNIAL Study.
Mone P, De Gennaro S, Moriello D, Frullone S, D'Amelio R, Ferrante MNV, Marro A, Santulli G.
Eur J Prev Cardiol. 2023;30(12):1283-1288. doi: 10.1093/eurjpc/zwad173.
237) A machine learning model identifies a functional connectome signature that predicts blood pressure levels: imaging insights from a large population of 35882 patients.
Avvisato R, Forzano I, Varzideh F, Mone P, Santulli G.
Cardiovasc Res. 2023;119:1458. doi: 10.1093/cvr/cvad065.
236) Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study.
Mone P, Martinelli G, Lucariello A, Leo AL, Marro A, De Gennaro S, Marzocco S, Moriello D, Frullone S, Cobellis L, Santulli G.
Cardiovascular Diabetology. 2023;22(1):94.
235) Wnt signaling in endocrine and metabolic disorders.
Cailotto F, Santulli G.
Front Endocrinol. 2023;14:1254977. doi: 10.3389/fendo.2023.1254977.
234) A novel urinary proteomic classifier predicts the risk of coronary artery disease.
Mone P, Tesorio T, De Donato A, Cioppa A, Jankauskas SS, Salemme L, Santulli G.
Eur J Prev Cardiol. 2023; Apr 19:zwad123. doi: 10.1093/eurjpc/zwad123.
233) L-Arginine in diabetes: clinical and preclinical evidence.
Forzano I, Avvisato R, Varzideh F, Jankauskas SS, Cioppa A, Mone P, Salemme L, Kansakar U, Tesorio T, Trimarco V, Santulli G.
Cardiovasc Diabetol. 2023;22(1):89.
232) Choline Supplementation Improves Cognitive Performance in Frail Hypertensive Patients: Novel Insights on Endothelial Function from the INTERVENTIONIST Study.
Mone P, Kansakar U, Lucariello A, Marro A, Pansini A, Varzideh F, Nittolo G, De Angelis L, Trimarco V, Martinelli G, De Luca A, Santulli G.
Eur J Prev Cardiol. 2023; Apr 18:zwad120. doi: 10.1093/eurjpc/zwad120.
231) Methods and applications in clinical and translational physiology.
Santulli G (Corresponding Author), Pabelick CM, Jan YK, Denise P, de Lucia C.
Front Physiol. 2023;14:1169544.
230) miR-4432 Targets FGFBP1 in Human Endothelial Cells.
Avvisato R, Mone P, Jankauskas SS, Varzideh F, Kansakar U, Gambardella J, De Luca A, Matarese A, Santulli G.
Biology. 2023;12(3):459. doi: 10.3390/biology12030459.
229) Choline supplements: An update.
Kansakar U, Trimarco V, Mone P, Varzideh F, Lombardi A, Santulli G.
Front Endocrinol. 2023;14:1148166.
228) Beneficial effects of L-Arginine in patients hospitalized for COVID-19: New insights from a randomized clinical trial.
Trimarco V, Izzo R, Lombardi A, Coppola A, Fiorentino G, Santulli G.
Pharmacol Res. 2023;191:106702.
227) Transcription factors and arrhythmogenesis.
Kao YH, Chen YJ, Higa S, Chattipakorn N, Santulli G.
Frontiers in Physiology. 2023;14:1169747.
226) Sortilin and hypertension.
Avvisato R, Jankauskas SS, Varzideh F, Kansakar U, Mone P, Santulli G.
Curr Opin Nephrol Hypertens. 2023;32(2):134-140.
225) Endothelial Dysfunction Drives CRTd Outcome at 1-Year Follow-Up: A Novel Role as Biomarker for miR-130a-5p.
Sardu C, Santulli G, Savarese G, Trotta MC, Sacra C, Santamaria M, Volpicelli M, Ruocco A, Mauro C, Signoriello G, Marfella L, D'Amico M, Marfella R, Paolisso G.
Int J Mol Sci. 2023;24(2):1510.
224) Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart Failure.
Avvisato R, Jankauskas SS, Santulli G.
J Pharmacol Exp Ther. 2023;384(1):227-230.
223) Reply to SGLT-2 inhibitors: Post-infarction interventional effects.
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Barbato E, Pizzi C.
Pharmacological Research. 2023;189:106664.
222) Hyperglycemia drives the transition from pre-frailty to frailty: The Monteforte study.
Mone P, De Gennaro S, Frullone S, Marro A, Santulli G.
European Journal of Internal Medicine (EJIM). 2023;111:135-137.
221) Linking lifestyle factors to cardiovascular risk through metabolomics: Insights from a large population of diabetic patients followed-up for 11 years.
Tesorio T, Mone P, de Donato A, Trimarco V, Santulli G.
Atherosclerosis. 2023;367:37-39.
220) Non-Coding RNAs in Clinical Practice: From Biomarkers to Therapeutic Tools.
Santulli G.
Journal of Pharmacology and Experimental Therapeutics. 2023;384:225-226.
219) Stress Hyperglycemia Drives the Risk of Hospitalization for Chest Pain in Patients With Ischemia and Nonobstructive Coronary Arteries (INOCA).
Mone P, Lombardi A, Salemme L, Cioppa A, Popusoi G, Varzideh F, Pansini A, Jankauskas SS, Forzano I, Avvisato R, Wang X, Tesorio T, Santulli G.
Diabetes Care. 2023;46(2):450-454.
218) Influence of lifestyle factors in the management of diabetes mellitus.
Sardu C, Santulli G, D' Onofrio N.
Front Endocrinol. 2023;14:1258766.
217) Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes.
Mone P, Lombardi A, Kansakar U, Varzideh F, Jankauskas SS, Pansini A, Marzocco S, De Gennaro S, Famiglietti M, Macina G, Frullone S, Santulli G.
J Pharmacol Exp Ther (JPET). 2023;384:116-122.
216) Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E.
Pharmacol Res. 2023;187:106597.
215) Mitochondrial microRNAs Are Dysregulated in Patients with Fabry Disease.
Gambardella J, Fiordelisi A, Sorriento D, Cerasuolo F, Buonaiuto A, Avvisato R, Pisani A, Varzideh F, Riccio E, Santulli G, Iaccarino G.
J Pharmacol Exp Ther. 2023;384(1):72-78.
214) Therapeutic concordance improves blood pressure control in patients with resistant hypertension.
Trimarco V, Izzo R, Mone P, Lembo M, Manzi MV, Pacella D, Falco A, Gallo P, Esposito G, Morisco C, Santulli G (Corresponding Author), Trimarco B.
Pharmacol Res. 2023;187:106557.
213) Targeting cardiovascular and metabolic disorders through annual nationwide screening and lifestyle intervention: insights from a cohort of 5 819 041 subjects with a 4-year follow-up.
Santulli G, Jankauskas SS, Varzideh F, Mone P, Kansakar U.
Eur J Prev Cardiol. 2023;30(4):329-330.
212) Exosomal miR-145 and miR-885 Regulate Thrombosis in COVID-19.
Gambardella J, Kansakar U, Sardu C, Messina V, Jankauskas SS, Marfella R, Maggi P, Wang X, Mone P, Paolisso G, Sorriento D, Santulli G.
J Pharmacol Exp Ther. 2023;384(1):109-115.
211) Endothelial dysfunction in long-COVID: New insights from the nationwide multicenter LINCOLN Study.
Trimarco V, Izzo R, Zanforlin A, Tursi F, Scarpelli F, Santus P, Pennisi A, Pelaia G, Mussi C, Mininni S, Messina N, Marazzi G, Maniscalco M, Mallardo M, Fazio G, Diana A, Capra Marzani M, Aloè T, Mone P, Trimarco B, Santulli G.
Pharmacol Res. 2022;185:106486.
210) Response to Comment on Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
Santulli G, Frullone S, Morgante M, Macina G, Pansini A, Gambardella J, Lombardi A, Mone P.
Diabetes Care. 2022;45(10):e151-e152.
209) Aprocitentan: New insights.
Varzideh F, Kansakar U, Jankauskas SS, Santulli G.
Front Cardiovasc Med. 2022;9:1093406.
208) miR-142 Targets TIM-1 in Human Endothelial Cells: Potential Implications for Stroke, COVID-19, Zika, Ebola, Dengue, and Other Viral Infections.
Kansakar U, Gambardella J, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Matarese A, Santulli G.
Int J Mol Sci. 2022;23(18):10242.
207) Beneficial effects of Vitamin C and L-Arginine in the treatment of post-acute sequelae of COVID-19.
Santulli G, Trimarco V, Trimarco B, Izzo R.
Pharmacol Res. 2022;185:106479.
206) Parkin Controls Cardiac Function in Obesity by Regulating Mitochondrial Calcium Uptake.
Jankauskas S, Kansakar U, De Donato A, Mone P, Varzideh F, Santulli G.
JACC Basic Transl Sci. 2022;7(8):797-799.
205) Tirzepatide: A Systematic Update.
Forzano I, Varzideh F, Avvisato R, Jankauskas SS, Mone P, Santulli G.
Int J Mol Sci. 2022;23(23):14631.
204) In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study.
Cesaro A, Gragnano F, Paolisso P, Bergamaschi L, Gallinoro E, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Oreglia JA, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Pizzi C, Barbato E, Calabrò P, Marfella R.
Front Cardiovasc Med. 2022;9:1012220.
203) From resveratrol to ISIDE11: how to activate SIRT1 and improve endothelial function? New therapeutic insights for methylenetetrahydrofolate reductase deficiency.
Jankauskas SS, Mone P, Santulli G.
Cell Mol Life Sci. 2022;79(8):451.
202) Stress Hyperglycemia Drives the Risk of Hospitalization for Chest Pain in Patients With Ischemia and Nonobstructive Coronary Arteries (INOCA).
Mone P, Lombardi A, Salemme L, Cioppa A, Popusoi G, Varzideh F, Pansini A, Jankauskas SS, Forzano I, Avvisato R, Wang X, Tesorio T, Santulli G.
Diabetes Care. 2022 Dec 7:dc220783. doi: 10.2337/dc22-0783.
201) Targeting endothelial dysfunction and oxidative stress in Long-COVID.
Trimarco V, Izzo R, Mone P, Trimarco B, Santulli G.
Pharmacol Res. 2022;184:106451.
200) Tirzepatide versus Semaglutide once weekly in Type 2 Diabetes.
Santulli G.
New England Journal of Medicine (NEJM). 2022;386(7):e17.
199) Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN Survey.
Izzo R, Trimarco V, Mone P, Aloè T, Capra Marzani M, Diana A, Fazio G, Mallardo M, Maniscalco M, Marazzi G, Messina N, Mininni S, Mussi C, Pelaia G, Pennisi A, Santus P, Scarpelli F, Tursi F, Zanforlin A, Santulli G (Corresponding Author), Trimarco B.
Pharmacol Res. 2022;183:106360.
198) SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients.
Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, Santulli G.
Hypertension 2022;79(8):1633-1643.
197) The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
Forzano I, Mone P, Varzideh F, Jankauskas SS, Kansakar U, De Luca A, Santulli G.
Front Endocrinol. 2022;13:1097968.
196) Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure.
Forzano I, Mone P, Mottola G, Kansakar U, Salemme L, De Luca A, Tesorio T, Varzideh F, Santulli G.
J Clin Med. 2022;11(24):7503.
195) Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.
Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Casella G, Mauro C, Vassilev D, Marfella R, Calabrò P, Barbato E, Pizzi C.
Cardiovasc Diabetol. 2022;21(1):77. doi: 10.1186/s12933-022-01506-8.
194) Functional role of miR-34a in diabetes and frailty.
Mone P, de Donato A, Varzideh F, Kansakar U, Jankauskas SS, Pansini A, Santulli G.
Front Aging. 2022 Jul 18;3:949924.
193) L-Arginine Improves Cognitive Impairment in Hypertensive Frail Older Adults.
Mone P, Pansini A, Jankauskas SS, Varzideh F, Kansakar U, Lombardi A, Trimarco V, Frullone S, Santulli G.
Front Cardiovasc Med. 2022;9:868521. doi: 10.3389/fcvm.2022.868521.
192) Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.
Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Nuccia M, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E.
Pharmacol Res. 2022;187:106597. doi: 10.1016/j.phrs.2022.106597.
191) High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients.
Trimarco V, Izzo R, Morisco C, Mone P, Virginia Manzi M, Falco A, Pacella D, Gallo P, Lembo M, Santulli G (Corresponding Author), Trimarco B.
Hypertension. 2022;79(10):2355-2363.
[With Cover and interview to Prof. Santulli published in Scientific American]
190) Nogo-A reduces ceramide de novo biosynthesis to protect from heart failure.
Sasset L, Manzo OL, Zhang Y, Marino A, Rubinelli L, Riemma MA, Chalasani MLS, Dasoveanu DC, Roviezzo F, Jankauskas SS, Santulli G, Bucci MR, Lu TT, Di Lorenzo A.
Cardiovasc Res. 2023;119(2):506-519.
189) Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and HFpEF.
Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, Frullone S, Santulli G.
Diabetes Care. 2022;45(5):1247-1251.
188) IP3 receptor orchestrates maladaptive vascular responses in heart failure.
Santulli G*, Dridi H* (*Co-First Authors), Gambardella J, Jankauskas SS, Yuan Q, Yang J, Reiken R, Wang X, Wronska A, Liu X, Lacampagne A, Marks A.
Journal of Clinical Investigation. 2022;132(4):e152859.
187) Sortilin drives hypertension by modulating sphingolipid/ceramide homeostasis and by triggering oxidative stress.
Varzideh F, Jankauskas SS, Kansakar U, Mone P, Gambardella J, Santulli G.
Journal of Clinical Investigation. 2022;132(3):e156624.
186) Bioengineering Strategies to Create 3D Cardiac Constructs from Human Induced Pluripotent Stem Cells.
Varzideh F, Mone P, Santulli G.
Bioengineering. 2022;9(4):168. doi: 10.3390/bioengineering9040168.
185) Updated ACC/AHA/HFSA 2022 Guidelines on Heart Failure: What’s New? From Epidemiology to Clinical Management.
Santulli G, Wang X, Mone P.
Eur Heart J (CVP). 2022;8(5):e23. doi: 10.1093/ehjcvp/pvac029.
184) Infarct Size, Inflammatory Burden, and Admission Hyperglycemia in Diabetic patients with Acute Myocardial Infarction Treated with SGLT2-Inhibitors: A Multicenter International Registry.
Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Casella G, Mauro C, Vassilev D, Marfella R, Calabrò P, Barbato E, Pizzi C.
Cardiovascular Diabetology. 2022;21(1):77.
183) Glycation of Ryanodine Receptor in circulating lymphocytes predicts the response to cardiac resynchronization therapy.
Gambardella J, Jankauskas SS, D’Ascia S, Sardu C, Matarese A, Minicucci F, Mone P, Santulli G.
The Journal of Heart and Lung Transplantation. 2022;41(4):438-441.
182) Exosome-Mediated Angiogenesis Underlies LVAD-Induced Bleeding in Patients With End-Stage Heart Failure.
Mone P, Pansini A, Varzideh F, de Donato A, Jankauskas SS, Santulli G.
JACC Basic Transl Sci. 2022;7(3):262-264. doi: 10.1016/j.jacbts.2022.01.011.
181) L-Arginine Enhances the Effects of Cardiac Rehabilitation on Physical Performance: New Insights for Managing Cardiovascular Patients During the COVID-19 Pandemic.
Mone P, Izzo R, Marazzi G, Manzi MV, Gallo P, Campolongo G, Cacciotti L, Tartaglia D, Caminiti G, Varzideh F, Santulli G, Trimarco V.
J Pharmacol Exp Ther. 2022;381:197-203. doi: 10.1124/jpet.122.001149.
180) Omega-3 fatty acids coordinate glucose and lipid metabolism in diabetic patients.
Mone P, Varzideh F, Kansakar U, Infante C, Lombardi A, de Donato A, Frullone S, Santulli G.
Lipids Health Dis. 2022;21(1):31.
179) Functional Role of microRNAs in Regulating Cardiomyocyte Death.
Kansakar U, Varzideh F, Mone P, Jankauskas SS, Santulli G.
Cells. 2022;11(6):983. doi: 10.3390/cells11060983.
178) Physical decline and cognitive impairment in frail hypertensive elders during COVID-19.
Mone P, Pansini A, Frullone S, de Donato A, Buonincontri V, De Blasiis P, Marro A, Morgante M, De Luca A, Santulli G.
European Journal of Internal Medicine. 2022;99:89-92. doi: 10.1016/j.ejim.2022.03.012.
177) Diabetes and restenosis.
Wilson S, Mone P, Kansakar U, Jankauskas SS, Donkor K, Adebayo A, Varzideh F, Eacobacci M, Gambardella J, Lombardi A, Santulli G.
Cardiovasc Diabetol. 2022;21(1):23. doi: 10.1186/s12933-022-01460-5.
176) Exosome-mediated angiogenesis underlies LVAD-induced bleeding in patients with end-stage heart failure.
Mone P, Pansini A, Varzideh F, de Donato A, Jankauskas SS, Santulli G.
JACC Basic Transl Science. 2022;7(3):262-264.
175) Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults.
Mone P, Gambardella J, Lombardi A, Pansini A, De Gennaro S, Leo AL, Famiglietti M, Marro A, Morgante M, Frullone S, De Luca A, Santulli G.
Cardiovasc Diabetol. 2022;21(1):10. doi: 10.1186/s12933-021-01442-z.
174) Epidemiology of Obstructive Sleep Apnea: What is the Contribution of Hypertension and Arterial Stiffness?
Mone P, Kansakar U, Varzideh F, Boccalone E, Lombardi A, Pansini A, Santulli G.
Journal of Clinical Hypertension. 2022;24(4):395-397.
173) Effects of insulin resistance on mitochondrial (dys)function.
Mone P, Morgante M, Pansini A, Jankauskas SS, Rizzo M, Lombardi A, Frullone S, Santulli G.
Atherosclerosis. 2022;341:52-54. doi: 10.1016/j.atherosclerosis.2021.11.026.
172) Cognitive dysfunction correlates with physical impairment in frail patients with acute myocardial infarction.
Mone P, Gambardella J, Pansini A, Martinelli G, Minicucci F, Mauro C, Santulli G.
Aging Clin Exp Res. 2022; 34(1):49-53. doi: 10.1007/s40520-021-01897-w.
171) Aspirin, NOACs, Warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021.
Mone P, Trimarco B, Santulli G.
Eur Heart J Cardiovasc Pharmacother. 2022;8(3):E7-E8. doi: 10.1093/ehjcvp/pvab081.
170) In permanent AF with narrow QRS, AV junction ablation + CRT vs. rate-control drug therapy reduced mortality.
Mone P, Santulli G.
Ann Intern Med. 2022;175(2):JC21. (IF: 51.6)
Invited commentary on “AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial” Eur Heart J. 2021;42(46):4731-4739.
169) A Platform (Authorships.org) for the Objective Qualification and Order of Academic Authorship in Medical and Science Journals: Development and Evaluation Study Using the Design Science Research Methodology.
Raptis DA, Raptis D, Tinguely P, Mettler T, Clavien PA, Zuber M, Lesurtel M, Graf R, Abidi SR, Ferraro D, Novelli S, Leung S, Palma A, Schütz T, Santulli G, et al. Authorships.org Collaborative
JMIR Form Res. 2022;6(3):e34258. doi: 10.2196/34258.
168) Global cognitive function correlates with P-wave dispersion in frail hypertensive older adults.
Mone P, Pansini A, Calabrò F, De Gennaro S, Esposito M, Rinaldi P, Colin A, Minicucci F, Coppola A, Frullone S, Santulli G.
J Clin Hypertens. 2022; 24(5):638-643. doi: 10.1111/jch.14439.
167) Hyperglycemia drives restenosis in STEMI patients.
Mone P, Gambardella J, Minicucci F, Lombardi A, Mauro C, Santulli G.
Diabetes Care. 2021;44(11):e192. doi: 10.2337/dc21-0939.
166) Heart Failure in Diabetes.
Jankauskas SS, Kansakar U, Varzideh F, Wilson S, Mone P, Lombardi A, Gambardella J, Santulli G.
Metabolism. 2021;125:154910. doi: 10.1016/j.metabol.2021.154910.
165) Role of endothelial miR-24 in COVID-19 cerebrovascular events.
Gambardella J, Coppola A, Izzo R, Fiorentino G, Trimarco B, Santulli G.
Critical Care. 2021;25(1):306. (IF: 19.3)
164) Effects of adding L-arginine orally to standard therapy in patients with COVID-19: A randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis.
Fiorentino G, Coppola A, Izzo R, Annunziata A, Bernardo M, Lombardi A, Trimarco V, Santulli G, Trimarco B.
The Lancet - eClinicalMedicine. 2021;40:101125. (IF: 17)
163) Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients with Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-up.
Sardu C, Massetti M, Testa N, Di Martino L, Castellano G, Turriziani F, Sasso FC, Torella M, De Feo M, Santulli G, Paolisso G, Marfella R.
Front Pharmacol. 2021;12:777083. doi: 10.3389/fphar.2021.777083.
162) L-Arginine and COVID-19: An Update.
Adebayo A, Varzideh F, Wilson S, Gambardella J, Eacobacci M, Jankauskas SS, Donkor K, Kansakar U, Trimarco V, Mone P, Lombardi A, Santulli G.
Nutrients. 2021;13(11):3951. doi: 10.3390/nu13113951.
161) Tackling SARS-CoV-2 Variants Using Specific miRNA Tools.
Renwick N, El-Osta A, Salamon I, Broseghini E, Ferracin M, Poliseno L, Jankauskas SS, Santulli G, Xiao H, Shiu PKT, Roy S, Goel A.
Noncoding RNA. 2021;7(3):58. doi: 10.3390/ncrna7030058.
160) Cardiovascular Endocrinology: Evolving Concepts and Updated Epidemiology of Relevant Diseases.
Varzideh F, Kansakar U, Jankauskas SS, Gambardella J, Santulli G.
Front Endocrinol. 2021;12:772876. doi: 10.3389/fendo.2021.772876.
159) Advances in the understanding of excitation-contraction coupling: the pulsing quest for drugs against heart failure and arrhythmias.
Kansakar U, Varzideh F, Jankauskas SS, Gambardella J, Trimarco B, Santulli G.
Eur Heart J Cardiovasc Pharmacother. 2021;7(6):e91-e93. doi: 10.1093/ehjcvp/pvab069.
158) Cognitive impairment in frail elderly with hypertension: role of hyperglycemia.
Mone P, Gambardella J, Pansini A, de Donato A, Martinelli G, Boccalone E, Matarese A, Frullone S, Santulli G.
Cells. 2021;10(8):2115. doi: 10.3390/cells10082115
157) Functional role of miR-155 in the pathogenesis of diabetes mellitus and its complications.
Jankauskas SS, Gambardella J, Sardu C, Lombardi A, Santulli G.
Noncoding RNA. 2021;7(3):39. doi: 10.3390/ncrna7030039.
156) SGLT2 inhibitors in cardiovascular medicine.
Varzideh F, Kansakar U, Santulli G.
Eur Heart J (Cardiovascular Pharmacotherapy). 2021;7(4):e67-e68.
155) A Retinoic Acid Receptor β2 agonist improves cardiac function in a heart failure model.
Tang XH*, Gambardella J* (*co First Author), Jankauskas SS, Wang X, Santulli G, et al.
JPET. 2021;379(2):182-10. doi: 10.1124/jpet.121.000806. (Journal Cover - Nov 2021)
154) miR-24 targets the transmembrane glycoprotein Neuropilin-1 in human brain microvascular endothelial cells.
Mone P, Gambardella J, Wang X, Jankauskas SS, Matarese A, Santulli G.
Noncoding RNA. 2021;7(1):9. doi: 10.3390/ncrna7010009.
153) Targeting the phenotypic switch of vascular smooth muscle cells to tackle atherosclerosis.
Kansakar U, Jankauskas SS, Gambardella J, Santulli G.
Atherosclerosis. 2021;324:117-120.
152) Mitochondrial remodeling and dynamic inter-organellar contacts in cardiovascular physiopathology.
Santulli G, Monaco G, Parra VM, Morciano G.
Front Cell Dev Biol. 2021;9:679725. doi: 10.3389/fcell.2021.679725.
151) Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk.
Santulli G, Jankauskas SS, Gambardella J.
European Heart Journal CVP. 2021 Feb 28:pvab014. doi: 10.1093/ehjcvp/pvab014.
150) Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk.
Wilson S, Mone P, Jankauskas SS, Gambardella J, Santulli G.
J Clin Hypertens. 2021;23(4):831-834. doi: 10.1111/jch.14186.
149) In patients with early AF and CV conditions, early rhythm-control therapy vs. usual care reduced CV events at 5 years.
Santulli G.
Ann Intern Med. 2021;174(1):JC6. doi: 10.7326/ACPJ202101190-006.
Invited commentary on “Early Rhythm-Control Therapy in Patients with Atrial Fibrillation” N Engl J Med. 2020;383(14):1305-1316.
148) Impact of thrombus aspiration in frail STEMI patients.
Mone P, Gambardella J, Pansini A, Rizzo M, Mauro C, Minicucci F, Santulli G.
Aging Clinical and Experimental Research (ACER) 2021; 33(11):3081-3089. doi: 10.1007/s40520-021-01848-5.
147) Thyroid hormones regulate both cardiovascular and renal mechanisms underlying hypertension.
Jankauskas SS, Morelli M, Gambardella J, Lombardi A, Santulli G.
J Clin Hypertens. 2021;23(2):373-381. doi: 10.1111/jch.14152.
146) What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions.
Gambardella J, Santulli G.
Eur Heart J (CVP). 2021;7(3):e2-e3. doi: 10.1093/ehjcvp/pvaa145.
145) The discovery and development of IP3 receptor modulators: An update.
Gambardella J, Morelli M, Wang X, Castellanos V, Mone P, Santulli G.
Expert Opin Drug Discov. 2021 Jan 6:1-10. doi: 10.1080/17460441.2021.1858792.
144) Effects of Chronic Supplementation of L-Arginine on Physical Fitness in Water Polo Players.
Gambardella J, Fiordelisi A, Spigno L, Boldrini L, Lungonelli G, Di Vaia E, Santulli G, Sorriento D, Cerasuolo FA, Trimarco V, Iaccarino G.
Oxid Med Cell Longev. 2021;2021:6684568. doi: 10.1155/2021/6684568.
143) Exploiting GRK2 Inhibition as a Therapeutic Option in Experimental Cancer Treatment: Role of p53-Induced Mitochondrial Apoptosis.
Gambardella J, Fiordelisi A, Santulli G, Ciccarelli M, Cerasuolo FA, Sala M, Sommella E, Campiglia P, Illario M, Iaccarino G, Sorriento D.
Cancers. 2020;12(12):3530.
142) Role of endothelial GRK2 in angioedema.
Gambardella J, Sorriento D, Bova M, Rusciano M, Loffredo S, Wang X, Petraroli A, Carucci L, Mormile I, Oliveti M, Morelli M, Fiordelisi A, Spadaro G, Campiglia P, Sala M, Trimarco B, Iaccarino G, Santulli G, Ciccarelli M.
Hypertension. 2020;76(5):1625-1636.
141) miR-98 regulates TMPRSS2 expression in human endothelial cells: Key implications for COVID-19.
Gambardella J, Matarese A, Sardu C, Santulli G.
BioMedicines. 2020;8(11):462. doi:10.3390/biomedicines8110462.
140) Genetics of adrenergic signaling drives coronary artery calcification.
Gambardella J, Wang X, Mone P, Khondkar W, Santulli G.
Atherosclerosis. 2020;310:88-90.
139) Metabolic flexibility of mitochondria plays a key role in balancing glucose and fatty acid metabolism in the diabetic heart.
Gambardella J, Lombardi A, Santulli G.
Diabetes. 2020;69(10):2054-2057.
138) Standardizing translational microbiome studies and metagenomics analyses.
Gambardella J, Castellanos V, Santulli G.
Cardiovascular Research. 2020;117(3):640-642.
137) Arginine and endothelial function.
Gambardella J, Khondkar W, Morelli M, Wang X, Santulli G, Trimarco V.
BioMedicines. 2020;8(8):277.
136) No Pleiotropic Effects of Linagliptin on Atherosclerotic Plaques: Case Closed.
Al-Mallah MH, Hyafil F, Santulli G.
Atherosclerosis. 2020;305:61-63. doi: 10.1016/j.atherosclerosis.2020.05.009.
135) Vitamin C and Cardiovascular Disease: An Update.
Morelli M, Gambardella J, Castellanos V, Trimarco V, Santulli G.
Antioxidants. 2020;9(12):1227. doi: 10.3390/antiox9121227.
134) miR-7 regulates GLP-1-mediated insulin release by targeting Beta-Arrestin 1.
Matarese A, Gambardella J, Lombardi A, Wang X, Santulli G.
Cells. 2020;9(7):1621.
133) Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence.
Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G.
J Clin Med. 2020;9(5):1417. doi: 10.3390/jcm9051417.
132) Cardiac BIN1 replacement therapy ameliorates inotropy and lusitropy in heart failure by regulating calcium handling.
Gambardella J, Wang XJ, Ferrara J, Morelli MB, Santulli G.
JACC BTS. 2020;5(6):579-581.
131) Is Endothelial Dysfunction the Concealed Cornerstone of COVID-19?
Santulli G, Morelli M, Gambardella J.
BMJ. 2020; e-letter.
130) Pathophysiological mechanisms underlying the beneficial effects of physical activity in hypertension.
Gambardella J, Morelli M, Wang X, Santulli G.
J Clin Hypertens. 2020;22(2):291-295.
129) COVID-19 and endothelial dysfunction.
Gambardella J, Sardu C, Santulli G.
JAMA. 2020; e-letter.
128) Implications of ABO blood group in hypertensive patients with COVID-19.
Sardu C, Marfella R, Maggi P, Messina V, Cirillo P, Codella V, Gambardella J, Sardu A, Gatta G, Santulli G, Paolisso G.
BMC Cardiovasc Disord. 2020;20(1):373. doi: 10.1186/s12872-020-01658-z.
127) Inositol 1,4,5-Trisphosphate Receptors in Human Disease: A Comprehensive Update.
Gambardella J, Lombardi A, Morelli MB, Ferrara J, Santulli G.
J Clin Med. 2020 Apr 12;9(4):1096.
126) A small molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy.
Amgalan D, Garner TP, Pekson R, Jia XF, Yanamandala M, Paulino V, Liang FG, Corbalan J, Lee J, Chen Y, Karagiannis GS, Sanchez LR, Liang H, Narayanagari SR, Mitchell K, Lopez A, Margulets V, Scarlata M, Santulli G, Asnani A, Peterson RT, Hazan RB, Condeelis JS, Oktay MH, Steidl U, Kirshenbaum LA, Gavathiotis E, Kitsis RN.
Nature Cancer. 2020;1(3):315-328. doi: 10.1038/s43018-020-0039-1.
125) In acute HF, intensive and sustained vasodilation did not reduce a composite of death or readmission at 180 days.
Santulli G.
Ann Intern Med. 2020;172(10):JC54. doi: 10.7326/ACPJ202005190-054.
Invited commentary on “Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients with Acute Heart Failure: The GALACTIC Randomized Clinical Trial.” JAMA. 322(23):2292-2302.
124) Modulation of SERCA in patients with persistent atrial fibrillation treated by epicardial thoracoscopic ablation: The CAMAF Study.
Sardu C, Santulli G, Guerra G, Trotta MC, Santamaria M, Sacra C, Testa N, Ducceschi V, Gatta G, D’ Amico M, Sasso FC, Paolisso G, Marfella R.
J Clin Med. 2020;9(2):544; doi: 10.3390/jcm9020544.
123) Calcium supplements: Good for the bone, bad for the heart? A systematic updated appraisal.
Morelli M, Santulli G, Gambardella J.
Atherosclerosis. 2020;296:68-73. doi: 10.1016/j.atherosclerosis.2020.01.008.
122) In AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplatelet agent in AF and stable CAD.
Santulli G.
Ann Intern Med. 2020;172(2):JC6. doi: 10.7326/ACPJ202001210-006.
Invited commentary on “Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease” N Engl J Med. 2019;381(12):1103-1113.
121) Cardiosomal microRNAs are essential in post-infarction myofibroblast phenoconversion.
Morelli MB, Shu J, Sardu C, Matarese A, Santulli G.
Int. J. Mol. Sci. 2020;21(1):201.
120) Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.
Morelli MB, Chavez C, Santulli G.
Expert Opin Ther Targets. 2020;24(1):79-88. doi: 10.1080/14728222.2020.1707806.
119) Cardiomyocyte-derived exosomal microRNA-92a mediates post-ischemic myofibroblast activation both in vitro and ex vivo.
Wang X, Morelli M, Matarese A, Sardu C, Santulli G.
ESC Heart Failure. 2020;7(1):284-288. doi: 10.1002/ehf2.12584.
118) Safety in numbers: identifying multiple targets for beta cell proliferation.
Santulli G.
Science Translational Medicine. 2019;11(475). doi: 10.1126/scitranslmed.aaw5312.
117) Catheter ablation improved quality of life more than drug therapy at 1 y in symptomatic atrial fibrillation.
Santulli G.
Ann Intern Med. 2019;171(2):JC10. doi: 10.7326/ACPJ201907160-010
Invited commentary on “Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients with Atrial Fibrillation: The CABANA Randomized Clinical Trial” JAMA. 2019;321(13):1275-1285 and “Effect of Catheter Ablation vs Antiarrhythmic Medication on Quality of Life in Patients with Atrial Fibrillation: The CAPTAF Randomized Clinical Trial” JAMA. 2019;321(11):1059-1068.
116) We are what we eat: Impact of food from short supply chain on metabolic syndrome.
Santulli G, Pascale V, Finelli R, Visco V, Giannotti R, Massari A, Morisco C, Ciccarelli M, Illario M, Iaccarino G, Coscioni E.
Journal of Clinical Medicine. 2019;8(12):2061. doi: 10.3390/jcm8122061.
115) Pre-eclampsia and future cardiovascular diseases: How to assess the risk?
Santulli G, Al-Mallah MH.
Atherosclerosis. 2019;290:136-137. doi: 10.1016/j.atherosclerosis.2019.07.004.
114) In type 2 diabetes, intensive glucose control for 5.6 years did not differ from usual care for major CV events at 14 years.
Santulli G.
Ann Intern Med. 2019 Sep 17;171(6):JC31. doi: 10.7326/ACPJ201909170-031.
Invited commentary on “Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up” N Engl J Med. 2019;380(23):2215-2224.
113) Heparanase in health and disease: the neglected housekeeper of the cell?
Shu J, Santulli G.
Atherosclerosis. 2019;283:124-126. doi: 10.1016/j.atherosclerosis.2019.01.017.
112) Exosomal microRNA: The revolutionary endogenous Innerspace nanotechnology.
Santulli G.
Science Translational Medicine. 2018;10(467):eaav9141.
111) Why is chronic obstructive pulmonary disease linked to atrial fibrillation? A systematic overview of the underlying mechanisms.
Matarese A, Sardu C, Shu J, Santulli G.
Int J Cardiol. 2019;276:149-151. doi: 10.1016/j.ijcard.2018.10.075.
110) Diabetes, body fat, skeletal muscle, and hypertension: The ominous chiasmus?
Shu J, Matarese A, Santulli G.
J Clin Hypertens. 2019;21(2):239-242.
109) Stroke prevention: Learning from the master (and COMMANDER).
Santulli G.
Science Translational Medicine. 2018;10(459):eaav0340. doi: 10.1126/scitranslmed.aav0340.
Invited commentary on “Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease” NEJM. 2018;379(14):1332-1342.
108) Dietary fat is a key determinant in balancing mitochondrial dynamics in heart failure: A novel mechanism underlying the obesity paradox.
De Rosa M, Gambardella J, Shu J, Santulli G.
Cardiovasc. Res. 2018;114(7):925-927. doi: 10.1093/cvr/cvy074.
107) Connecting myofibroblasts and cardiomyocytes via extracellular vesicle-associated microRNA: A short-distance affair.
Xiao H, Shiu PKT, Shu J, Santulli G, Gheybi M, Conn SJ, Bogard B, Hubé F, Taube JH, Mani SA, Song L, Calin GA, Zhang S.
Non-coding RNA. 2018;18;4.
106) Cardioprotective effects of autophagy: Eat your heart out, heart failure!
Santulli G.
Science Transl. Med. 2018;10(443). pii: eaau0462. doi: 10.1126/scitranslmed.aau0462
105) Update on peripheral artery disease: Epidemiology and evidence based facts.
Shu S, Santulli G.
Atherosclerosis. 2018;275:379-381. doi: 10.1016/j.atherosclerosis.2018.05.033
104) In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years.
Santulli G.
Ann Intern Med. 2018;169(12):JC67. doi: 10.7326/ACPJC-2018-169-12-067.
Invited commentary on "Effects of aspirin for primary prevention in persons with diabetes mellitus" NEJM. 2018;379:1529-39.
103) The lymphatic border patrol outwits inflammatory cells in myocardial infarction.
Santulli G.
Science Translational Medicine. 2018; Vol. 10, Issue 451, eaau7379; doi: 10.1126/scitranslmed.aau7379. (Editors' Choice)
102) The amino-terminal domain of GRK5 inhibits cardiac hypertrophy through the regulation of calcium/calmodulin dependent transcription factors.
Sorriento D, Santulli G, Ciccarelli M, Maione AS, Illario M, Trimarco B, Iaccarino G.
Int J Mol Med. 2018;19(3):861. doi: 10.3390/ijms19030861.
101) Ryanodine Receptor calcium leak in circulating B-lymphocytes as a biomarker in heart failure.
Kushnir A, Santulli G, Reiken SR, Coromilas E, Godfrey SJ, Brunjes DL, Colombo PC, Yuzefpolskaya M, Sokol SI, et al.
Circulation. 2018; 138(11):1144-1154.
F1000 recommended article.
100) Overlooking cardiac dysfunction triggered by immune checkpoint inhibitors: Caution, trespassers will be ventilated!
Santulli G.
Science Translational Medicine. 2018;10(435):eaat3888. doi: 10.1126/scitranslmed.aat3888.
99) Effectiveness of new generation drug-eluting stents in ostial right coronary artery lesions.
De Rosa M, Santulli G.
International Journal of Cardiology. 2018;254:84-86.
98) Ryanodine receptor structure and function in health and disease.
Santulli G, Lewis DR, Marks A, Frank J.
Subcellular Biochemistry. 2018;87:329-352.
F1000 recommended article.
97) Endothelial cells: The heart attack of the Clones.
Santulli G.
Science Translational Medicine. 2018;10(427):eaar7529. doi: 10.1126/scitranslmed.aar7529.
96) Mechanistic role of Beta2 adrenergic receptor in glucose homeostasis.
Santulli G, Iaccarino G.
Circulation. 2017; doi: 10.7916/D89310HZ.
95) Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells.
Lombardi A, Gambardella J, Du XL, Sorriento D, Mauro M, Iaccarino G, Trimarco B, Santulli G.
Sci. Reports. 2017;7:15823.
94) Quit smoking to outsmart atherogenesis: Molecular mechanisms underlying clinical evidence
Gambardella J, Sardu C, Sacra C, Del Giudice C, Santulli G.
Atherosclerosis. 2017;257:242-245.
93) Impaired mitochondrial calcium uptake caused by tacrolimus underlies beta-cell failure.
Lombardi A, Trimarco B, Iaccarino G, Santulli G.
Cell Commun. 2017 Nov 13;15(1):47. doi: 10.1186/s12964-017-0203-0.
92) Opposite effects of Beta2-adrenoceptor gene deletion on insulin signaling in liver and skeletal muscle.
Cipolletta E, Del Giudice C, Santulli G, Trimarco B, Iaccarino G.
Nutr Metab Cardiovasc Dis. 2017;27:615-623. doi: 10.1016/j.numecd.2017.05.011.
91) Physiology and pathophysiology of excitation-contraction coupling: the functional role of ryanodine receptor.
Santulli G, Lewis DR, et al.
J Muscle Res Cell Motil. 2017;38:47-45.
90) Mechanistic role of kinases in the regulation of mitochondrial fitness.
Sorriento D, Gambardella J, Fiordelisi A, Trimarco B, Ciccarelli M, Iaccarino G, Santulli G.
Adv Exp Med Biol. 2017;982:521-528. doi: 10.1007/978-3-319-55330-6-26.
89) Linking inflammation and beta cell death: the functional role of microRNA.
Achour C, Bogard B, Hubé F, Mani SA, Santulli G, Taube JH.
Non-Coding RNA. 2017;3(2):21.
88) Effects of alpha-lipoic acid on multiple cytokines and biomarkers and recurrence of atrial fibrillation within one year of catheter ablation.
Sardu C, Santulli G, Santamaria M, Barbieri M, Sacra C, Paolisso P, D’Amico F, Testa N, Caporaso I, Paolisso G, Marfella R, Rizzo MR.
Am J Cardiol. 2017;119:1382-1386.
87) Functional role of mitochondria in arrhythmogenesis.
Gambardella J, Sorriento D, Ciccarelli M, Del Giudice C, Fiordelisi A, Napolitano L, Trimarco B, Iaccarino G, Santulli G.
Adv Exp Med Biol. 2017;982:191-202. doi: 10.1007/978-3-319-55330-6_10.
86) Dietary components and metabolic dysfunction: Translating preclinical studies into clinical practice.
Santulli G.
Nutrients. 2016;13;8(10). pii: E632.
85) Childhood obesity and education.
Santulli G.
The Lancet Diabetes & Endocrinology. 2016;4(11):957.
84) Intracellular calcium release channels: an update.
Santulli G, Nakashima R, et al.
Journal of Physiology. 2017;595:3041-3051.
83) The possible role of chromosome X variability in hypertensive familiarity.
Ciccarelli M, Finelli R, Santulli G, Rivera N,
Journal of Human Hypertension (Nature Publishing Group). 2017;31:37-42.
82) Integrating diet and inflammation to calculate cardiovascular risk.
Gambardella G, Santulli G.
Atherosclerosis. 2016,253:258-261. doi: 10.1016/j.atherosclerosis.2016.08.041.
81) Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the TELECART Study.
Sardu C, Santamaria M, Rizzo MR, Barbieri M, di Marino M, Paolisso G, Santulli G, Marfella R.
Int J Clinical Practice. 2016;70:569-76.
80) Microbiome and MicroRNA mediate the communication between gut and vasculature.
Gautheret D, Taube J, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, et al.
Non-Coding RNA. 2016;2(3)9.
79) Maintenance of normal blood pressure is dependent on IP3R1-mediated regulation of eNOS.
Yuan Q*, Yang J*, Santulli G.* (*co-First Authorship; Corresponding Author), Reiken S, Wronska A, Kim M, Osborne BW, et al.
PNAS. 2016;113:8532-8537.
78) Adrenergic signaling in heart failure and cardiovascular aging.
Santulli G, Iaccarino G.
Maturitas. 2016;93:65-72.
77) Leaky ryanodine receptors contribute to diaphragmatic weakness during mechanical ventilation.
Matecki S, Dridi H, Jung B, Saint N, Reiken SR, Scheuermann V, Mrozek S, Santulli G, Umanskaya A, Petrof B, Jaber S, et al.
PNAS. 2016;113(32):9069-74 (Direct Submission)
76) MicroRNAs distinctively regulate vascular smooth muscle and endothelial cells: functional implications in angiogenesis, atherosclerosis, and in-stent restenosis.
Santulli G.
Adv Exp Med Biol. 2015;887:53-77.
75) Micromanipulating the behavior via microRNA: New lessons from Drosophila.
Berindan-Neagoe I, Calin GA, Francastel C, Hubé F, Santulli G.
Non-Coding RNA. 2015;1:285-288.
74) Mitochondrial calcium overload is a key determinant in heart failure.
Santulli G, Xie W, et al.
PNAS. 2015;112:11389-94 (with Editorial Commentary).
F1000 recommended article; Highly cited article (Thomson Reuters: Top 1% in Biomedicine)
73) Models for preclinical studies in aging-related disorders: One is not for all.
Santulli G, Borras C, Bousquet J, Calzà L, Cano A, Illario M, Franceschi C, Liotta G, Molloy WD, et al.
Transl Med @ UniSa. 2016;13:4-12.
72) Mechanistic role of microRNAs in coupling lipid metabolism and atherosclerosis.
Novák J, Olejníčková V, Tkáčová N, Santulli G.
Adv Exp Med Biol. 2015;887:79-100.
71) An interview with Gaetano Santulli.
Santulli G.
European Medical Journal (EMJ). 2015;3.2:35-37.
70) microRNAs and endothelial (dys) function.
Santulli G.
J Cell Physiol. 2015;231:1638-1644. (Invited Review)
69) A leaky endoplasmic reticulum calcium channel impairs insulin secretion
Santulli G.
JCI Impact 2015;May Issue:p10. Editor’s picks.
68) Essential roles of intracellular calcium release channels in muscle, brain, and metabolism.
Santulli G. et al.
Current Molecular Pharmacology. 2015;8:206-22.
67) Exploiting microRNA specificity and selectivity: Paving a sustainable path towards precision medicine.
Santulli G.
Adv Exp Med Biol. 2015;888:1-3.
66) Targeting the CaMKII/ERK interaction in the heart prevents cardiac hypertrophy.
Cipolletta E, Rusciano MR, Maione AS, Santulli G, Sorriento D, et al.
PLoS One. 2015;10(6):e0130477.
65) Integrating GRK2 and NFkappaB in the pathophysiology of cardiac hypertrophy.
Sorriento D, Santulli G, Franco A, et al.
J Card Transl Res. 2015; 8:493-502.
64) Mitochondrial oxidative stress promotes atrial fibrillation.
Xie W*, Santulli G* (*co-First Authorship), Reiken SR, Yuan Q, Osborne B, et al.
Sci Reports. 2015;5:11427.
63) Mitochondrial calcium overload and oxidative stress in cardiomyocytes are linked by microRNA.
Francastel C, Hubé F, Mani S, Santulli G, et al.
Non-Coding RNA. 2015;1:167-169.
62) Calcium release channel RyR2 regulates insulin release and glucose homeostasis.
Santulli G, Pagano G, Sardu C, Xie W, Reiken S, D'Ascia SL, Cannone M, Marziliano N, Trimarco B, et al.
Journal of Clinical Investigation. 2015;125(5):1968-1978.
Highly cited article (Thomson Reuters: Top 1% in Biomedicine)
61) A Fleeting Glimpse Inside microRNA, Epigenetics, and Micropeptidomics.
Santulli G.
Adv Exp Med Biol. 2015;887:1-14.
60) Application of microRNAs in diagnosis and treatment of cardiovascular disease.
Wronska A, Kurkowska-Jastrzebska I, Santulli G.
Acta Physiol. 2015;213(1):60-83.
Highly cited article (Thomson Reuters: Top 1% in Biomedicine)
59) Beta-blockers in diabetic patients with heart failure.
Santulli G.
JAMA Internal Medicine. 2015;175(4):657.
58) Effects of low-carbohydrate and low-fat diets.
Santulli G.
Ann Intern Med. 2015;162(5):392.
57) Functional role of Calstabin2 in age-related cardiac alterations.
Yuan Q*, Chen Z*, Santulli G* (*co-First Authorship), Gu L, Yang ZG, Yuan ZQ, et al.
Sci Reports. 2014;4:7425.
56) Genetically enhancing mitochondrial antioxidant activity improves muscle function in aging.
Umanskaya U*, Santulli G* (*co-First Authorship), Xie W, et al.
PNAS USA. 2014;111:15250-5.
55) MicroRNA-directed gene delivery selectively targets VSMCs to prevent restenosis.
Santulli G.
Journal of Clinical Investigation. 2014;online-only.
54) Diabetes Ask1ng for trouble: Terminating microRNA biogenesis in ER stress.
Ferracin M, Gautheret D, Hubé F, Mani SA, Mattick JS, Ørom UA, Santulli G, Slotkin RK, et al.
Non-Coding RNA. 2015;1:87-93.
53) Myoregulin is a novel modulator of calcium handling and excitation–contraction coupling: Hunting for Easter eggs in the concealed microproteome.
Ferracin M, Gautheret D, Hubé F, Mani S, Mattick J, Ørom UA, Santulli G, Slotkin RK, Szweykowska-Kulinska Z, Taube JH, et al.
Non-Coding RNA. 2015;1:87-93.
52) An interview with Gaetano Santulli.
Nguyen FT, Patel C, Santulli G.
JCI Impact 2014; September Issue:p10. Editor’s picks.
51) A selective microRNA-based strategy inhibits restenosis while preserving endothelial function.
Santulli G, Wronska A, Uryu K, Diacovo TG, Gao M, Marx SO, Kitajewski J, Chilton JM, Akat KM, Tuschl T, et al.
Journal of Clinical Investigation. 2014;124:4102-4114 (with Editorial Commentary).
Highly cited article (Thomson Reuters: Top 1% in Biomedicine)
50) Functional role of miRNA in cardiac resynchronization therapy.
Sardu C, Marfella R, Santulli G, Paolisso G.
Pharmacogenomics. 2014;15:1159-1168.
49) Chest pain, panic disorder and coronary artery disease: A systematic review.
Fonseca Soares-Filho GL, Arias-Carrión O, Santulli G, Silva AC, Machado S, et al.
CNS Neurol Disord Drug Targets. 2014;13:992-1001.
48) CaMKII protects MKP-1 from proteasome degradation in endothelial cells.
Ciccarelli M, Rusciano M, Sorriento D, Basilicata MF, Santulli G, Campiglia P, et al.
Cell Signal. 2014;26:2167-74.
47) Trafficking GRK2: Cellular and metabolic consequences of GRK2 subcellular localization.
Sorriento D, Ciccarelli M, Santulli G, Illario M, Trimarco B, Iaccarino G.
Transl Med @ UniSa. 2014;10: 3–7.
46) Impact of diabetes mellitus on the clinical response to cardiac resynchronization therapy in elderly people.
Sardu C, Marfella R, Santulli G.
J Card Transl Res. 2014;7:362-368.
45) Atrial fibrillation and MicroRNAs.
Santulli G, Iaccarino G, De Luca N, Trimarco B, Condorelli G.
Frontiers in Physiology. 2014;24;5:15.
44) Metabolic syndrome is associated with a poor outcome in patients affected by outflow tract premature ventricular contractions treated by catheter ablation.
Sardu C, Carreras G, Katsanos S, Kamperidis V, Pace MC, Passavanti MB, Fava I, Paolisso P, Pieretti G, Francesco Nicoletti GF, Santulli G, Paolisso G, Marfella R.
BMC Card Disord. 2014;14:176.
43) Adrenal signaling in heart failure: Something more than a distant ship's smoke on the horizon.
Santulli G.
Hypertension. 2014;63:215-6.
42) Angiopoietin-like proteins: A comprehensive look.
Santulli G.
Frontiers in Endocrinology. 2014;2;5:4.
41) Tailoring mTOR-based therapy: molecular evidence and clinical challenges.
Santulli G, et al.
Pharmacogenomics. 2013;14:1517-26.
40) Myocardial perfusion imaging study of CO2-induced panic attack.
Soares-Filho GLF, Machado S, Arias-Carrión O, Santulli G, Mesquita CT, et al.
American Journal of Cardiology. 2013;113:384-8.
39) Imaging atrial arrhythmic intracellular calcium in intact heart.
Xie W, Santulli G, Guo X, Gao M, et al.
J Mol Cell Cardiol (JMCC). 2013;64:120-3.
38) Physical activity ameliorates cardiovascular health in elderly subjects: the functional role of the β adrenergic system.
Santulli G, Ciccarelli M, Trimarco B, Iaccarino G.
Frontiers in Physiology. 2013;4:209.
37) G-Protein-coupled receptor kinase 2 and hypertension: Molecular insights and pathophysiological mechanisms.
Santulli G, Trimarco B, Iaccarino G.
High Blood Press & Cardiovasc Prev. 2013;20:5-12. (with Editorial commentary).
36) The essential role of β2-adrenergic receptor in glucose homeostasis.
Santulli G, Iaccarino G.
PLoS One. 2013;e-pages.
35) Pinpointing beta adrenergic receptor in ageing pathophysiology: Victim or executioner? Evidence from crime scenes.
Santulli G, Iaccarino G.
Immun Ageing. 2013;15;10:10.
34) Epidemiology of cardiovascular disease in the 21st century: Updated numbers and updated facts.
Santulli G.
JCvD. 2013;1:1-2.
33) Angiogenesis in chronic obstructive pulmonary disease: A translational appraisal.
Matarese A, Santulli G.
Nature Prec. 2012; doi: 10.1038/npre.2012.7112.1.
32) Development of atrial fibrillation in recipients of cardiac resynchronization therapy: the role of atrial reverse remodelling.
Santulli G, D’ascia SL, D’ascia C.
Can J Cardiol. 2012;28:245.e17–245.e18.
31) The impact of left ventricular size on response to cardiac resynchronization therapy.
Santulli G, D’ascia S, D’ascia C.
Am Heart J. 2012;163:e11.
30) CaMK4 gene deletion induces hypertension.
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, et al.
JAHA. 2012;1:e001081.
29) Coronary heart disease risk factors and mortality.
Santulli G.
Journal of the American Medical Association - JAMA. 2012;307:1137.
28) Endothelial cells are able to synthesize and release catecholamines both in vitro and in vivo.
Sorriento D, Santulli G, Del Giudice C, Anastasio A, Trimarco B, Iaccarino G.
Hypertension. 2012;60:129-136.
27) Role of cardiac resynchronization therapy in the development of new-onset atrial fibrillation: A single-center prospective study.
Santulli G, Chiariello M, D’Ascia C, D’Ascia S.
Nature Prec. 2012; https://www.nature.com/articles/npre.2012.7137.1
doi: 10.1038/npre.2012.7137.1
26) Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus.
Santulli G.
Neurology. 2012;78:840.
25) Atrial remodelling in echocardiographic super-responders to cardiac resynchronization therapy.
Santulli G, D’Ascia C.
Heart. 2012;98:517.
24) Age-related impairment in insulin release: the essential role of Beta2 Adrenergic Receptor.
Santulli G, Lombardi A, Sorriento D, Anastasio A, Del Giudice C, Formisano P, et al.
Diabetes. 2012;61:692-701.
23) Atrial function in patients undergoing CRT.
Santulli G, D’Ascia SL, Marino V, D’Ascia C.
JACC Imaging. 2012;5:124-125.
22) Mitochondrial localization unveils a novel role for GRK2 in organelle biogenesis.
Fusco A, Santulli G, Sorriento D, Cipolletta E, Garbi C, Dorn GW, et al.
Cell Signal. 2012;24:468-475.
21) Angiogenesis in chronic obstructive pulmonary disease.
Matarese A, Santulli G.
Transl Med @ UniSa. 2012;3:49–56.
20) G protein-coupled receptor kinase 2 in patients with acute myocardial infarction.
Santulli G, Campanile A, Spinelli L, Assante di Panzillo E, Ciccarelli M, et al.
Am J Cardiol. 2011;107:1125-1130.
19) Evaluation of the anti-angiogenic properties of the new selective alphaVbeta3 integrin antagonist RGDechiHCit.
Santulli G, Basilicata MF, De Simone M, Del Giudice C, Anastasio A, Sorriento D, et al.
J Transl Med. 2011;9:7.
18) Cardiac resynchronization therapy response predicts occurrence of atrial fibrillation in non-ischemic dilated cardiomyopathy.
D’Ascia S, D’Ascia C, Marino V, Chiariello M, Santulli G.
Int J Clinical Practice. 2011;69:1149-1155.
17) Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ.
Perino A, Ghigo A*, Ferrero E*, Morello F*, Santulli G, Baillie GS, et al.
Molecular Cell. 2011;42:84-95.
16) Impaired neoangiogenesis in Beta2-adrenoceptor gene-deficient mice: restoration by intravascular human Beta2-adrenoceptor gene transfer and role of NFκB and CREB transcription factors.
Ciccarelli M, Sorriento D, Santulli G, Zhou R, Eckhart A, Peppel K, Koch WJ, et al.
British Journal of Pharmacology. 2011;162:712-721.
15) Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-kappaB-dependent hypertrophic gene expression.
Sorriento D*, Santulli G* (*co-First Authorship), Fusco A, Anastasio A, et al.
Hypertension. 2010;56:696-704.
14) The GPIIIA PlA2 polymorphism is associated with an increased risk of cardiovascular adverse events.
Galasso G, Santulli G, Piscione F, De Rosa R, Piccolo R, Cassese S, et al.
BMC Cardiovasc Dis. 2010;10:41.
13) Advanced algorithms can lead to electrocardiographic misinterpretations.
D’Ascia S, Santulli G, Liguori V, Marino V, Chiariello M, et al.
International Journal of Cardiology. 2010;141:e34-e36.
12) In vivo properties of the proangiogenic peptide QK.
Santulli G, Ciccarelli M, Palumbo G, Campanile A, Galasso G, Ziaco B, et al.
J Transl Med. 2009;7:41.
11) A new synthetic protein, TAT-RH, inhibits tumor growth through the regulation of NF-kappa-B activity.
Sorriento D, Campanile A, Santulli G, Leggiero E, Pastore L, et al.
Molecular Cancer. 2009;8:97.
10) The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance.
Cipolletta E, Campanile A, Santulli G, Sanzari E, Leosco D, Campiglia P, et al.
Cardiovasc Res. 2009;84:407-415.
9) Overproduction of phosphoprotein enriched in diabetes (PED) induces mesangial expansion and upregulates protein kinase C-beta activity and TGF-beta1 expression.
Oriente F., Iovino S., Cassese A., Romano C., Miele C., Troncone G., Balletta M., Perfetti A., Santulli G., Iaccarino G., et al.
Diabetologia. 2009;52:2642-2652.
8) The G-protein-coupled receptor kinase 5 inhibits NFκB transcriptional activity by inducing nuclear accumulation of IκBα.
Sorriento D, Ciccarelli M, Santulli G, Campanile A, Altobelli GG, Cimini V, et al.
PNAS. 2008;195:17818-17823.
7) Enhanced GRK2 Expression and Desensitization of βAR Vasodilatation in Hypertensive Patients.
Izzo R, Cipolletta E, Ciccarelli M, Campanile A, Santulli G, Palumbo G, et al.
Clinical and Translational Science. 2008;1:215-220.
6) Endothelial Alpha-1 Adrenergic Receptors Regulate Neo-angiogenesis.
Ciccarelli M, Santulli G, Campanile A, Galasso G, Cervèro P, et al.
British J Pharmacol. 2008;153:936-946.
5) The PlA1/A2 polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: Increased risk of ischemic stroke in high-risk patients.
Lanni F, Santulli G, Izzo R, Rubattu S, Zanda B, Volpe M, et al.
J Hypertension. 2007;25:551-556.
4) Endothelial β2 adrenergic signaling to AKT: Role of Gi and SRC.
Ciccarelli M, Cipolletta E, Santulli G, et al.
Cell Signal. 2007;19:1949-1955.
3) G Protein-Coupled Receptor Kinases and Hypertension: A Review of Disease Mechanisms
Iaccarino G, Campanile A, Santulli G, Zuppieri F, Koch WJ.
High Blood Pressure & Cardiovascular Prevention. 2006;13(4):151-158.
2) Ischemic neoangiogenesis enhanced by β2-adrenergic receptor overexpression - A novel role for the endothelial adrenergic system
Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, et al.
Circulation Research. 2005;97:1182-1189.
1) AKT Participates in Endothelial Dysfunction in Hypertension.
Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, Paudice A, Elia A, Santulli G, Campanile A, Arcucci O, Pastore L, Salvatore F, et al.
Circulation. 2004;109:2587-2593.
-Books:
-INFLUENCE OF LIFESTYLE FACTORS IN THE MANAGEMENT OF DIABETES MELLITUS. Apple Books - Frontiers Media. Editors: Gaetano Santulli, Celestino Sardu, Nunzia D’Onofrio (2023) ISBN: 978-2-8325-3345-1; DOI 10.3389/978-2-8325-3345-1.
-TRANSLATIONAL ASPECTS OF CARDIOVASCULAR BIOLOGY: FROM BENCH TO BEDSIDE. Hardcover Book, eds. MDPI. Editor: Gaetano Santulli (2023) ISBN: 978-3-0365-7575-9.
-METHODS AND APPLICATIONS IN CLINICAL AND TRANSLATIONAL PHYSIOLOGY: eds. Frontiers. Editors: Claudio De Lucia, Christina Maria Pabelick, Yih-Kuen Jan, Gaetano Santulli, Pierre Denise (2023) ISBN: 9782832520437.
-CARDIOVASCULAR DISEASE: FROM MOLECULAR MECHANISMS TO CLINICAL THERAPIES. eds. MDPI. Editor: Gaetano Santulli (2021).
-MITOCHONDRIAL REMODELING AND DYNAMIC INTER-ORGANELLAR CONTACTS IN CARDIOVASCULAR PHYSIOPATHOLOGY. eds. Frontiers. Editors: Gaetano Santulli, Giovanni Monaco, Valentina Parra, Giampaolo Morciano (2021).
-CARDIOVASCULAR DISEASE AND DIABETES: A JOURNEY FORM BENCH TO BEDSIDE. eds. Frontiers. Editor: Gaetano Santulli (2019).
-MITOCHONDRIAL DYNAMICS IN CARDIOVASCULAR MEDICINE. Hardcover Book (646 pages) – eds. Springer-Nature. Editor: Gaetano Santulli (2017).
-DIET AND METABOLIC DYSFUNCTON. Hardcover Book – eds. MDPI, Basel, Switzerland. Adapted from the Special Issue published in Nutrients. Editor: Gaetano Santulli (2017).
-microRNA: FROM MOLECULAR BIOLOGY TO CLINICAL PRACTICE. Hardcover Book – 3 volumes, eds. Springer Editor: Gaetano Santulli (2016).
-ADRENAL GLANDS: FROM PATHOPHYSIOLOGY TO CLINICAL PRACTICE. Hardcover Book, eds. Nova Publishers Inc. Editor: Gaetano Santulli (2015).
-ANGIOGENESIS: INSIGHTS FROM A SYSTEMATIC OVERVIEW. Hardcover Book, eds. Nova Publishers Inc. Editor: Gaetano Santulli (2013).
-Book chapters:
-Gaetano Santulli, et al. microRNAs in diabetes. In “MicroRNA: From Bench to Bedside”. Editor: Dr. J. Xiao; eds. Elsevier (2022).
-Gaetano Santulli, Daniel Lewis, Andrew Marks, and Joachim Frank. Ryanodine receptor structure and function in health and disease. In “Membrane-bound Macromolecular Protein Complexes: Structure and Function”. Editors: Dr. J. Robin Harris and E. Boekema; eds. Springer-Nature (2018).
-Daniela Sorriento, Gaetano Santulli, et al. The Amino-Terminal Domain of GRK5 Inhibits Cardiac Hypertrophy through the Regulation of Calcium/Calmodulin Dependent Transcription Factors. In “Calcium Signaling in Human Health and Diseases”. Editor: F. Moccia, eds. MDPI (2018).
-Jessica Gambardella, Bruno Trimarco, Guido Iaccarino, and Gaetano Santulli (Corresponding Author). New Insights in Cardiac Calcium Handling and Excitation-Contraction Coupling. In “Heart Failure: From Research to Clinical Practice”. Editor: Shaidul Islam (Karolinska Institutet), eds. Springer-Nature (2017).
-Michele Ciccarelli, Daniela Sorriento, Enrico Coscioni, Guido Iaccarino, Gaetano Santulli (Corresponding Author). Adrenergic Receptors. In “Endocrinology of the heart in health and disease”. Editors: JC. Schisler, CH. Lang, MS. Willis, eds. Elsevier (2016).
-Gaetano Santulli, (Corresponding Author) et al. Essential roles of intracellular calcium release channels in muscle, brain and metabolism. In “50th Anniversary of Calcium Channel Research: Biomedical Perspectives”. eds. Bentham Science, Potomac, MD, USA (2015).
-Gaetano Santulli. The adrenergic system in cardiovascular metabolism and aging. In “The cardiovascular adrenergic system”. Hardcover Book, Editor: A. Lymperopoulos, eds. Springer (2018).
-Gaetano Santulli. Sympathetic Nervous System Signaling in Heart Failure and Cardiac Aging. In “Pathophysiology and Pharmacotherapy of Cardiovascular Disease”. Editor: G. Jagadeesh, eds. Springer (2015).